Accessibility Menu
PolyPid logo

PolyPid(NASDAQ) PYPD

Market Cap$83.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-99%
5 Year-98%
1 Year+28%
1 Month-13%
$4.45
+2.06%
+0.09Today
After hours$4.42-$0.03 (-0.67%)
PolyPid last closing stock price
MetricPriceDate
Last closeUSD 4.362026-08-03
PolyPid stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+9.55%USD 3.982026-07-27
1 month-13.15%USD 5.022026-07-02
3 month-3.11%USD 4.502026-05-05
Year to date+0.46%USD 4.342025-12-31
1 year+27.86%USD 3.412025-08-01
3 year-62.36%USD 11.582023-08-04
5 year-98.07%USD 226.202021-08-04
Since inception-99.24%USD 570.002020-06-26

PolyPid Financials at a Glance

Market Cap

$83.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$33.63M

EPS (TTM)

-$1.91

P/E Ratio

-2.28

Dividend

$0.00

Beta (Volatility)

0.92 (Low)

Price

$4.45

Volume

165,911

Open

$4.37

Previous Close

$4.45

Daily Range

$4.35 - $4.60

52-Week Range

$3.06 - $5.73

Estimated Earnings Date

Aug 12, 2026

PYPD News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PolyPid

PolyPid Ltd. is an advanced-stage biopharmaceutical company focused on developing therapeutic solutions using its proprietary polymer-lipid encapsulation matrix (PLEX) platform. The company aims to address significant unmet medical needs, with its leading product candidate, D-PLEX100, currently in Phase III clinical trials for preventing surgical site infections.

Products and Services
  • D-PLEX100: A product candidate for preventing surgical site infections
  • Proprietary PLEX platform: Innovative technology for drug delivery
  • Focus on unmet medical needs: Targeting critical healthcare challenges
Growth Outlook
  • Phase III trials for D-PLEX100 could lead to market approval
  • Strong pipeline of future therapeutic solutions under development
  • Increasing demand for effective infection prevention solutions in healthcare
Financial Highlights
  • Recent quarterly net income of -$7.73 million, reflecting ongoing R&D investments
  • Cash and short-term investments of $11.1 million as of March 31, 2026
  • Market capitalization of approximately $38.1 million, indicating growth potential
PolyPid Ltd. operates in the biotechnology sector, emphasizing innovative solutions to improve patient outcomes. The company's focus on D-PLEX100, which is undergoing critical clinical trials, positions it well within the healthcare landscape. The proprietary PLEX platform enhances drug delivery, potentially revolutionizing treatment protocols for surgical site infections. Recent financial data indicates a commitment to research and development, with significant investments aimed at bringing D-PLEX100 to market. The company maintains a solid cash position, which supports ongoing operations and development efforts. As the healthcare industry increasingly prioritizes infection prevention, PolyPid's innovative solutions may meet a growing demand, presenting an intriguing opportunity for potential investors.
AI Generated • Jul 22, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

75

CEO

Dikla Czaczkes Akselbrad, MBA, CPA

Website

www.polypid.com

Headquarters

Petah Tikva, HM 4959376, IL

PYPD Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-241.96%

Return on Capital

-239.43%

Return on Assets

-175.52%

Earnings Yield

-43.86%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$83.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

19.08M

Volume

165.91K

Avg. Volume

214.22K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$16.09M

EBITDA

-$32.68M

Operating Cash Flow

$0.00

Capital Expenditure

$0.00

Free Cash Flow

$0.00

Cash & ST Invst.

$11.10M

Total Debt

$2.34M

PolyPid Performance Analysis

PolyPid annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
PolyPid sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
PolyPid annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.04-10.5%
20232023-12-31USD -16.99734.6%
20242024-12-31USD -4.91-71.1%
20252025-12-31USD -2.09-57.4%
PolyPid sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-11.4%
Q32025-09-3052.6%
Q42025-12-31-10.8%
Q12026-03-3114.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$83.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.16M

N/A

Employees

72

N/A

Net Income

-$7.73M

+6.5%

EBITDA

-$7.73M

-2.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$11.10M

+38.1%

Total Debt

$2.34M

-73.5%

Accounts Receivable

$0.00

N/A

Inventory

$1.11M

N/A

Long Term Debt

$383.00K

-73.1%

Short Term Debt

$1.96M

-73.5%

Return on Assets

-1.76%

N/A

Return on Invested Capital

-1.33%

N/A

Free Cash Flow

$0.00

N/A

Operating Cash Flow

$0.00

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PDSBPDS Biotechnology Corporation
$0.72+0.78%
VERUVeru Inc.
$2.37+4.87%
ANVSAnnovis Bio, Inc.
$1.87+8.72%
BTAIBioXcel Therapeutics, Inc.
$0.86+1.53%

Trending Stocks

Symbol / CompanyPricePrice Chg
PLTRPalantir Technologies
$162.66+0.29%
SPCXSpace Exploration Technologies
$125.33+0.09%
NVDANvidia
$211.94+0.03%
INTCIntel
$100.86+0.11%

Questions About PYPD

What is the current price of PolyPid?

PolyPid is trading at $4.45 per share.

What is the 52-week range for PolyPid?

Over the past 52 weeks, PolyPid has traded between $3.06 and $5.73.

How much debt does PolyPid have?

As of the most recent reporting period, PolyPid reported total debt of $2.34M.

How much cash does PolyPid have on hand?

PolyPid reported $9.08M in cash and cash equivalents in its most recent financial results.

What is PolyPid’s dividend yield?

PolyPid does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services